Theranostics: Paintball targeting of cancer cells combined with precision therapy

September 13, 2017
Research in this supplement covers current applications of theranostics and new, cutting-edge research on theranostics for a range of cancers. Credit: SNMMI

The Journal of Nuclear Medicine's September 2017 supplement shines a spotlight on theranostics and its increasingly important role in the delivery of precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed—minimizing side effects and improving quality of life for patients.

"Theranostics is the future of ," explains Wolfgang A. Weber, MD, chief of the Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. "Therapies are not selected based on genetic mutations that may or may not be present in all cells, but on imaging the whole patient and determining if a specific treatment can be effective. Because of the specific targeting of the , theranostic agents are extremely well tolerated."

This JNM Supplement on Clinical and Translational Theranostics is edited by Ken Herrmann, MD, MBA, chair of at the University of Duisburg-Essen, Essen, Germany, and Steven M. Larson, MD, and Weber, both at MSKCC. Their introductory article points out that theranostics is "more than just a fashion trend." It notes that "the idea of using a radioactive compound for , target-expression confirmation, and radionuclide therapy dates back to 1946, when Seidlin et al. published the first study on radioiodine therapy for metastatic thyroid cancer. More recently, sodium-iodine-124 and sodium-iodine-131 (Na124I/Na131I) have become important for thyroid cancer monitoring.

Today, Herrmann says, "The theranostic concept has gained new momentum with the recent success of peptide receptor radioligand therapy (PRRT) in neuroendocrine tumors (NETs)." He adds, "The current expansion of this concept to prostate cancer targeting the prostate specific membrane antigen (PSMA) is bringing theranostics to another level. Both are already in clinical use, with PRRT for NETs awaiting FDA approval at any moment."

In the video below Ken Herrmann, MD, MBA, chair of nuclear medicine at the University of Duisburg-Essen, Essen, Germany, explains the importance of theranostics.

Articles in the JNM supplement cover research on multireceptor targeting and new strategies for both PSMA imaging/therapy and targeting the somatostatin receptor (so effectively used in PRRT for NETs), as well as exciting research on theranostics for other cancers, including intraarterial yttrium-90 (90Y) therapy for liver metastases. Herrmann points out, "Additional promising theranostic research includes targeting the CXCR4-receptor in hematooncological tumors, the neurotensin 1 receptor in pancreatic cancer, Ewing sarcoma and gastrointestinal tumors, as well as alpha-MSH1 [alpha-melanocyte-stimulating hormone 1] in melanoma."

For nuclear , Weber says, "Theranostics will be practice-changing. Right now, nuclear medicine is dominated by hybrid imaging (PET/CT, SPECT/CT). Theranostics will bring and patient care to the center of nuclear medicine. In other words, the field will change from 'nuclear radiology' to true 'nuclear medicine.'"

Weber emphasizes, "The most important future development is to combine theranostics with other cancer therapies and use theranostics earlier in the course of disease in order to achieve not only prolongation of survival, but cures."

As Herrmann notes, "This is just the beginning of the era of theranostics!"

Explore further: Double targeting ligands to identify and treat prostate cancer

Related Stories

Double targeting ligands to identify and treat prostate cancer

September 7, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The new approach utilizes a single molecule designed ...

Theranostic drug personalizes prostate cancer imaging and therapy

June 8, 2015
A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting ...

Targeted photodynamic therapy shown highly effective against prostate cancer

June 12, 2017
Researchers presenting a preclinical study at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated the efficacy and optimal dose for targeted photodynamic therapy (tPDT) to ...

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics

June 30, 2017
Cancer is one of leading causes of human mortality around the world. The current mainstream cancer treatment modalities (e.g. surgery, chemotherapy and radiotherapy) only show limited treatment outcomes, partly owing to the ...

Personalized PRRT improves radiation delivery to neuroendocrine tumors

June 12, 2017
Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient dose of peptide-receptor radionuclide ...

Blood test predicts success of neuroendocrine cancer therapy

June 13, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear ...

Recommended for you

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.